1T
1T3.F Syndax Pharmaceuticals Inc
- Market cap
- EUR 766M
- P/E
- -
- P/B
- 76.68x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 1T3.F undervalued?
Graham numberThe Graham number of Syndax Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Syndax Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Syndax Pharmaceuticals Inc yet.
Syndax Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid le…
Full company profileSyndax Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Syndax Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.22M | 2.11M | 1.52M | 1.52M | 1.52M | 140M | 127M | 0.00 | 23.7M | 172M | 295M |
| Gross Profit | - | - | - | - | - | - | 0.00 | 0.00 | 22.9M | 165M | 268M |
| Operating Income | -43.8M | -62.0M | -75.9M | -57.5M | -71.4M | 26.2M | -152M | -230M | -340M | -273M | -155M |
| EBITDA | - | -61.9M | -75.8M | -57.4M | -70.7M | - | -146M | -209M | -314M | -252M | -139M |
| Net Income | -44.5M | -60.8M | -74.0M | -56.0M | -73.2M | 24.9M | -149M | -209M | -319M | -285M | -189M |
| EPS | - | -2.49 | -2.98 | -2.07 | -1.53 | 0.46 | -2.19 | -2.47 | -3.72 | -3.27 | -2.10 |
| Balance Sheet | |||||||||||
| Total Assets | 109M | 137M | 83.9M | 63.5M | 301M | 450M | 497M | 613M | 725M | 530M | 693M |
| Total Liabilities | 24.9M | 32.9M | 30.9M | 31.9M | 48.4M | 41.3M | 29.8M | 58.7M | 437M | 465M | 710M |
| Shareholders' Equity | 84.1M | 104M | 53.0M | 31.6M | 252M | 408M | 467M | 554M | 288M | 64.6M | -17.2M |
| Cash & Short-term Investments | 23.8M | 35.2M | 33.8M | 24.6M | 115M | 222M | 74.4M | 295M | 154M | 135M | 136M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -35.2M | -47.4M | -68.5M | -50.6M | -71.3M | 29.1M | -134M | -161M | -275M | -323M | -144M |
| Capital Expenditure | 261K | 84.0K | 187K | 129K | 129K | 129K | 0.00 | 0.00 | 0.00 | 187K | 0.00 |
| Free Cash Flow | - | -47.5M | -68.7M | -50.6M | -71.3M | 29.0M | -134M | -161M | -275M | -323M | -144M |
| Ratios | |||||||||||
| ROE | -52.9% | -58.3% | -139.4% | -177.4% | -29.0% | 6.1% | -31.9% | -37.8% | -110.6% | -441.6% | - |
| ROA | -40.8% | -44.3% | -88.1% | -88.2% | -24.3% | 5.5% | -30.0% | -34.2% | -44.0% | -53.9% | -27.2% |
| Net Profit Margin | -3,645.2% | -2,884.3% | -4,875.5% | -3,694.6% | -4,822.5% | 17.8% | -118.0% | - | -1,346.1% | -165.6% | -64.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Syndax Pharmaceuticals Inc dividends
Syndax Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Syndax Pharmaceuticals Inc
- Insiders 1.67%
- Institutions 98.33%
- Public & others 0.00%
- Shares outstanding 90.0M
- Free float 81.2M
Syndax Pharmaceuticals Inc company profile
- Company name
- Syndax Pharmaceuticals Inc
- Ticker
- 1T3.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 298
- Fiscal year end
- December
- Address
- 730 Third Avenue, New York, NY, United States, 10017
- Phone
- 781 419 1400
- Website
- syndax.com
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Syndax Pharmaceuticals Inc management
6- Mr. Michael A. Metzger M.B.A.CEO & Director · born 1971
- Mr. Steven ClosterChief Commercial Officer · born 1969
- Dr. Nicholas A.J. Botwood B.Sc., MBBSHead of Research & Development and Chief Medical Officer · born 1968
- Dr. Peter Ordentlich B.Sc., Ph.D.Co-Founder & Chief Scientific Officer · born 1969
- Dr. Richard A. Heyman Ph.D.Co-Founder · born 1957
- Dr. Michael Downes Ph.D.Co-Founder